Lapatinib-d4

• Description :

  Lapatinib-d4 is the deuterium labeled Lapatinib (HY-50898) . Lapatinib is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively[1][2].

• Product Name Alternative :

  GW572016-d4; GW2016-d4

• UNSPSC :

  12352005

• Target :

  Autophagy; EGFR; Ferroptosis

• Type :

  Isotope-Labeled Compounds

• Related Pathways :

  Apoptosis; Autophagy; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Purity :

  99.02

• Solubility :

  10 mM in DMSO|DMSO : 125mg/mL (ultrasonic)

• Smiles :

  CS(C([2H])([2H])C([2H])([2H])NCC1=CC=C(O1)C2=CC(C(NC3=CC(Cl)=C(C=C3)OCC4=CC(F)=CC=C4)=NC=N5)=C5C=C2)(=O)=O

• Molecular Formula :

  C29H22D4ClFN4O4S

• Molecular Weight :

  585.08

• References & Citations :

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.|[2]Rusnak DW, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther. 2001 Dec;1 (2) :85-94.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Isotope-Labeled Compounds

• Clinical Information :

  No Development Reported

• CAS Number :

  [1184263-99-7]